← All trials
NCT02908958
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2014
- Primary completion
- Jun 1, 2017
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Zhejiang UniversityOverall official - principal investigator
- First People's Hospital of HangzhouCollaborator
- Central South UniversityCollaborator
- Shaoxing Second HospitalCollaborator
- Sun Yat-Sen UniversityCollaborator
- Shandong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang Chinese Medical UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Xiamen UniversityCollaborator
- Hacettepe UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.